announcement today about FDA clearance for use in diabetic ulcers ect.
thinking to myself
aroa still a biological product and Novosorb synthetic.
but why hasnt PNV commented or made any specific moves to market Novosorb in this space.
Aroa value the TAM for it as 1b+ in US alone.
does anyone know of any case studies or comments from management Around use to novosorb in chronic wounds with healing compromised by disease (diabetes)
cheers
Aroa Discussion
-
- There are more pages in this discussion • 43 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PNV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.43 |
Change
-0.090(3.57%) |
Mkt cap ! $1.678B | |||
| Open | High | Low | Value | Volume |
| $2.49 | $2.50 | $2.43 | $2.311M | 940.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 17100 | $2.43 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.45 | 5973 | 1 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| PNV (ASX) Chart |